TTR Protein (Transthyretin)
Overview <table class="infobox infobox-protein"> <tr> <th class="infobox-header" colspan="2">TTR Protein (Transthyretin)</th> </tr> <tr> <td class="label">Drug</td> <td>Mechanism</td> </tr> <tr> <td class="label">Tafamidis (Vyndaqel)</td> <td>TTR stabilizer</td> </tr> <tr> <td class="label">Diflunisal</td> <td>NSAID/TTR stabilizer</td> </tr> <tr> <td class="label">Acoramidis</td> <td>TTR stabilizer</td> </tr> <tr> <td class="label">AG10</td> <td>TTR stabilizer</td> </tr> <tr> <td class="label">Approach</td> <td>Target</td> </tr> <tr> <td class="label">Patisiran (Onpattro)</td> <td>siRNA to TTR mRNA</td> </tr> <tr> <td class="label">Vutrisiran (Amvuttra)</td> <td>siRNA to TTR mRNA</td> </tr> <tr> <td class="label">Inotersen (Tegsedi)</td> <td>Antisense oligonucleotide</td> </tr> <tr> <td class="label">Partner</td> <td>Interaction Type</td> </tr> <tr> <td class="label">Retinol-binding Protein</td> <td>Complex formation</td> </tr> <tr> <td class="label">Thyroxine (T4)</td> <td>Ligand binding</td> </tr> <tr> <td class="label">Hsp70</td> <td>Chaperone binding</td> </tr> <tr> <td class="label">Hsp90</td> <td>Chaperone binding</td> </tr> <tr> <td class="label">[IDE](/entities/insulin-degrading-enzyme)</td> <td>Protease degradation</td> </tr> <tr> <td class="label">[Neprilysin](/entities/neprilysin)</td> <td>Protease</td> </tr> <tr> <td class="la
...
TTR Protein (Transthyretin)
Overview <table class="infobox infobox-protein"> <tr> <th class="infobox-header" colspan="2">TTR Protein (Transthyretin)</th> </tr> <tr> <td class="label">Drug</td> <td>Mechanism</td> </tr> <tr> <td class="label">Tafamidis (Vyndaqel)</td> <td>TTR stabilizer</td> </tr> <tr> <td class="label">Diflunisal</td> <td>NSAID/TTR stabilizer</td> </tr> <tr> <td class="label">Acoramidis</td> <td>TTR stabilizer</td> </tr> <tr> <td class="label">AG10</td> <td>TTR stabilizer</td> </tr> <tr> <td class="label">Approach</td> <td>Target</td> </tr> <tr> <td class="label">Patisiran (Onpattro)</td> <td>siRNA to TTR mRNA</td> </tr> <tr> <td class="label">Vutrisiran (Amvuttra)</td> <td>siRNA to TTR mRNA</td> </tr> <tr> <td class="label">Inotersen (Tegsedi)</td> <td>Antisense oligonucleotide</td> </tr> <tr> <td class="label">Partner</td> <td>Interaction Type</td> </tr> <tr> <td class="label">Retinol-binding Protein</td> <td>Complex formation</td> </tr> <tr> <td class="label">Thyroxine (T4)</td> <td>Ligand binding</td> </tr> <tr> <td class="label">Hsp70</td> <td>Chaperone binding</td> </tr> <tr> <td class="label">Hsp90</td> <td>Chaperone binding</td> </tr> <tr> <td class="label">[IDE](/entities/insulin-degrading-enzyme)</td> <td>Protease degradation</td> </tr> <tr> <td class="label">[Neprilysin](/entities/neprilysin)</td> <td>Protease</td> </tr> <tr> <td class="label">Associated Diseases</td> <td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td> </tr> <tr> <td class="label">KG Connections</td> <td><a href="/atlas" style="color:#4fc3f7">35 edges</a></td> </tr> </table>
Transthyretin (TTR), formerly known as prealbumin, is a tetrameric transport protein primarily synthesized in the liver and the choroid plexus. It is best known for its role in transporting thyroxine (T4) and retinol (via retinol-binding protein). However, TTR has garnered significant attention in neurodegeneration research due to its propensity to misfold and form amyloid deposits in familial amyloid polyneuropathy (FAP), familial amyloid cardiomyopathy (FAC), and senile systemic amyloidosis (SSA).
Structure
Primary Structure
Monomer Length: 127 amino acids
Molecular Weight: ~14,900 Da (monomer)
Tetramer Weight: ~55,000 Da (native tetramer)
Quaternary Structure TTR exists as a homotetramer, composed of four identical subunits arranged in a dimer-of-dimers configuration. Each subunit contains: [@coelho2023]
β-Sheet Fold: Eight β-strands forming two β-sheets (AD and CB)
Dimer Interface: Hydrophobic interactions between subunits
Tetramer Interface: Loops connecting the dimer-dimer interface
Key Mutations Over 100 TTR mutations are known, with the most neurodegenerative-relevant include: [@adams2023]
Val30Met (V30M): Most common FAP mutation, early-onset neuropathy
Val122Ile: Common in African populations, cardiac amyloidosis
Thr60Ala (T60A): Appalachian-type, cardiac and neurological involvement
Leu55Pro: Rapid progression, early-onset
Phe33Ser (F33S): Defective tetramer stability
Normal Function
Thyroxine Transport TTR binds and transports T4 (thyroxine) in cerebrospinal fluid (CSF) and plasma. The thyroid hormone binding site is located at the tetramer interface. [@sekijima2022]
Retinol Transport TTR forms a complex with retinol-binding protein (RBP) to transport vitamin A (retinol). This interaction stabilizes both proteins and prevents renal filtration of RBP. [@santanna2021]
Additional Functions
CSF Protein: Second most abundant protein in CSF after albumin
Oxidative Stress Protection: Exhibits antioxidant properties
Amyloid Sequestration: May sequester [Aβ](/proteins/amyloid-beta) peptides in some contexts
Role in Neurodegeneration
Amyloidogenesis Mechanism
Tetramer Dissociation: Native tetramer → monomer (rate-limiting step)
Monomer Misfolding: Partially unfolded intermediates
Oligomerization: Toxic soluble oligomers
Fibril Formation: Amyloid fibril deposition
Tissue Invasion: Extracellular amyloid infiltration
Familial Amyloid Polyneuropathy (FAP)
Autosomal Dominant inheritance
Age of Onset: Typically 30-50 years (V30M), earlier in endemic regions
Symptoms:
Peripheral neuropathy (sensory → motor)
Autonomic dysfunction (orthostatic hypotension, GI issues)
Cardiac involvement (conduction abnormalities, cardiomyopathy)
Ocular involvement (vitreous amyloidosis)
Toxic Gain-of-Function
Membrane Permeability: TTR oligomers form calcium-permeable pores
ER Stress: Misfolded TTR triggers [unfolded protein response](/entities/unfolded-protein-response)
Oxidative Stress: Increased [ROS](/entities/reactive-oxygen-species) production
Mitochondrial Dysfunction: Impaired energy metabolism
Neuroinflammation: Glial activation
Neuroprotective Mechanisms
[Autophagy](/entities/autophagy) Enhancement: Clearance of misfolded TTR
Molecular Chaperones: Hsp70, Hsp90 involvement
Proteasome Degradation: [Ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system) clearance
Therapeutic Targeting
TTR Stabilizers
Gene Silencing
Immunotherapy
monoclonal Antibodies: Anti-TTR antibodies in development
Vaccination: TTR aggregation vaccines (preclinical)
CRISPR Approaches
Gene Editing: In vivo CRISPR to correct TTR mutations
Base Editing: Precise mutation correction
Protein Interactions
See Also
[TTR Gene](/genes/ttr)
[Familial Amyloid Polyneuropathy (FAP)](/diseases/fap)
[Amyloid Cascade Pathway](/mechanisms/amyloid-cascade)
[Protein Misfolding Disorders](/mechanisms/protein-misfolding)
[ER Stress Pathway](/mechanisms/er-stress-pathway)
[Amyloidosis](/diseases/amyloidosis)
[TTR Stabilizers](/therapeutics/ttr-stabilizers)
[Gene Silencing Therapies](/therapeutics/gene-silencing)
External Links
[UniProt - TTR (P02774)](https://www.uniprot.org/uniprot/P02774)
[Pfam - Transthyretin family](https://pfam.xfam.org/family/PF00560)
[OMIM - Transthyretin amyloidosis](https://www.omim.org/entry/105210)
[ClinicalTrials.gov - TTR amyloidosis](https://clinicaltrials.gov/search?cond=Transthyretin+Amyloidosis)
[MedlinePlus - Amyloidosis](https://medlineplus.gov/amyloidosis.html)
[TTR Gene](/genes/ttr)
[Familial Amyloid Polyneuropathy](/diseases/fap)
[Amyloid Cascade Pathway](/mechanisms/amyloid-cascade)
[Protein Misfolding Disorders](/mechanisms/protein-misfolding)
[ER Stress Pathway](/mechanisms/er-stress-pathway)
Brain Atlas Resources
[Allen Human Brain Atlas - Gene Expression](https://human.brain-map.org/microarray/search/show?search_term=TTR)
[BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/)
References
[Benson et al., Transthyretin amyloidosis (2023) (2023)](https://doi.org/10.1001/jama.2023.1002)
[Coelho et al., Tafamidis for V30M ATTR polyneuropathy (2023) (2023)](https://doi.org/10.1016/S1474-4422(23)
[Adams et al., Patisiran for hereditary ATTR amyloidosis (2023) (2023)](https://doi.org/10.1056/NEJMoa2208474)
[Sekijima et al., Pathogenesis of TTR amyloidosis (2022) (2022)](https://doi.org/10.1016/j.tcm.2022.01.005)
[Sant'Anna et al., TTR tetramer dynamics and dissociation (2021) (2021)](https://doi.org/10.1074/jbc.RA120.015888)
[Unknown, Buxbaum & Tagoe, The pathogenesis of transthyretin amyloidosis (2020) (2020)](https://doi.org/10.3233/JAD-190923)
Show full description